For research teamsHelp me find a study
Back to all studies
CompletedNCT00367835

SPD503 (Guanfacine Hydrochloride) for ADHD

This study is completed in the United States. It is testing SPD503 (Guanfacine Hydrochloride) for ADHD.

ADHDDrugFrom 6 Years to 12 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore recruiting studies on this topic

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether SPD503 (Guanfacine hydrochloride) may be useful for children experiencing ADHD.

What would participation involve?

Participants may receive SPD503 (Guanfacine hydrochloride), attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in the United States.

Who is it mainly for?

This study appears to be mainly for children with ADHD. Because it involves minors, a parent or guardian may need to be involved.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)

  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: December 4, 2006
Recruitment status
Completed
Enrollment listed in the registry
217
Sponsor
Shire
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 6 Years to 12 Years
Official registry ID
NCT00367835
Official title
A Double-Blind, Randomized, Multi-Center, Flexible Dose Study Evaluating the Efficacy and Safety of SPD503 (Guanfacine Hydrochloride) in Children Aged 6-12 With Symptoms of Oppositionality and a Diagnosis of Attention Deficit/Hyperactivity Disorder

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT00367835. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

United States · 34 sites
  • HOPE Research Institute
    Phoenix, Arizona
    Site status: Not listed — confirm with the team
  • Valley Clinical Research
    El Centro, California
    Site status: Not listed — confirm with the team
  • Peninsula Research Associates Inc
    Rolling Hills Estates, California
    Site status: Not listed — confirm with the team
  • Sarkis Clinical Trials
    Gainesville, Florida
    Site status: Not listed — confirm with the team
  • University of Florida
    Gainesville, Florida
    Site status: Not listed — confirm with the team
  • Amedica Research Institute, Inc
    Hialeah, Florida
    Site status: Not listed — confirm with the team
  • CORE Research, Inc
    Maitland, Florida
    Site status: Not listed — confirm with the team
  • Miami Research Associates
    Miami, Florida
    Site status: Not listed — confirm with the team
  • Clinical Neuroscience Solutions, Inc
    Orlando, Florida
    Site status: Not listed — confirm with the team
  • Childrens Developmental Center
    Winter Park, Florida
    Site status: Not listed — confirm with the team
  • Capstone Clinical Research
    Libertyville, Illinois
    Site status: Not listed — confirm with the team
  • Vince and Associates Clinical Research
    Overland Park, Kansas
    Site status: Not listed — confirm with the team
  • Pedia Research
    Owensboro, Kentucky
    Site status: Not listed — confirm with the team
  • Four Rivers Clinical Research
    Paducah, Kentucky
    Site status: Not listed — confirm with the team
  • University of Nebraska Medical Center
    Omaha, Nebraska
    Site status: Not listed — confirm with the team
  • CRI Worldwide, LLC
    Clementon, New Jersey
    Site status: Not listed — confirm with the team
  • Mount Sinai School of Medicine
    New York, New York
    Site status: Not listed — confirm with the team
  • University of Rochester, School of Medicine and Dentistry
    Rochester, New York
    Site status: Not listed — confirm with the team
  • SUNY Upsate Medical University
    Syracuse, New York
    Site status: Not listed — confirm with the team
  • Piedmont Neuropsychiatry
    Charlotte, North Carolina
    Site status: Not listed — confirm with the team
  • Duke Child & Family Study Center
    Durham, North Carolina
    Site status: Not listed — confirm with the team
  • University of Cincinnati
    Cincinnati, Ohio
    Site status: Not listed — confirm with the team
  • Discovery and Wellness Center for Children
    Cleveland, Ohio
    Site status: Not listed — confirm with the team
  • BHI Inc
    Moore, Oklahoma
    Site status: Not listed — confirm with the team
  • IPS Research Company
    Oklahoma City, Oklahoma
    Site status: Not listed — confirm with the team
  • Oregon Center for Clinical Investigations, Inc
    Portland, Oregon
    Site status: Not listed — confirm with the team
  • Oregon Center for Clinical Investigations, Inc
    Salem, Oregon
    Site status: Not listed — confirm with the team
  • CRI Worldwide, LLC
    Philadelphia, Pennsylvania
    Site status: Not listed — confirm with the team
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania
    Site status: Not listed — confirm with the team
  • Claghorn-Lesem Research Clinic Inc
    Houston, Texas
    Site status: Not listed — confirm with the team
  • Red Oak Psychiatry Associates, PA
    Houston, Texas
    Site status: Not listed — confirm with the team
  • NeuroScience, Inc
    Herndon, Virginia
    Site status: Not listed — confirm with the team
  • Dominion Clinical Research
    Midlothian, Virginia
    Site status: Not listed — confirm with the team
  • Eastside Therapeutic Resource
    Kirkland, Washington
    Site status: Not listed — confirm with the team
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving SPD503 (Guanfacine hydrochloride), Placebo. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.

Who might this study be for?

This study may concern people with adhd; age range: From 6 Years to 12 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Shire, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.